Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $79.8 million.

  • Lyell Immunopharma's Non-Current Assets fell 5284.98% to $79.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414.9 million, marking a year-over-year decrease of 3888.69%. This contributed to the annual value of $111.3 million for FY2024, which is 4304.12% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Non-Current Assets is $79.8 million, which was down 5284.98% from $103.2 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Non-Current Assets high stood at $567.2 million for Q3 2021, and its period low was $79.8 million during Q3 2025.
  • Its 5-year average for Non-Current Assets is $258.6 million, with a median of $218.5 million in 2023.
  • In the last 5 years, Lyell Immunopharma's Non-Current Assets soared by 7236.43% in 2021 and then crashed by 5284.98% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Non-Current Assets (Quarter) stood at $501.1 million in 2021, then plummeted by 42.87% to $286.3 million in 2022, then tumbled by 31.76% to $195.3 million in 2023, then tumbled by 43.04% to $111.3 million in 2024, then dropped by 28.31% to $79.8 million in 2025.
  • Its Non-Current Assets stands at $79.8 million for Q3 2025, versus $103.2 million for Q2 2025 and $120.6 million for Q1 2025.